Roche News | finanzen.ch

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil	Trading-Depot	Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Trading-Depot

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

24.10.22	Roche Gets FDA Clearance For COVID-19 PCR Test For Use On Automated Cobas 6800/8800 Systems (RTTNews)
18.10.22	Roche 9-month Sales Up 2%; Confirms 2022 Outlook (RTTNews)
12.10.22	Genentech : Evrysdi Data Show Improvement Or Maintenance Of Motor Function In People With SMA (RTTNews)
11.10.22	Roche: PRAME (EPR20330) Antibody Evaluates PRAME Protein Expression In Suspected Melanoma Patients (RTTNews)
04.10.22	Roche's PATHWAY Anti-HER2 (4B5) Test Gets FDA Approval To Identify Patients Eligible For ENHERTU (RTTNews)
19.09.22	Roche granted FDA clearance for cobas pure integrated solutions for low- to mid-volume laboratories (PR Newswire)
19.09.22	Roche's Vabysmo Gets EU Approval To Treat Two Major Causes Of Vision Loss (RTTNews)
09.09.22	Roche's VENTANA PD-L1 (SP263) Assay receives CE IVD approval to identify patients with locally advanced and metastatic non-small cell lung cancer eligible for Libtayo (PR Newswire)
07.09.22	Roche To Buy Good Therapeutics Conditionally Active PD-1-regulated IL-2 Program (RTTNews)
29.08.22	Teva: Ranivisio, Biosimilar To Lucentis, Approved In Europe For Age-related Macular Degeneration (RTTNews)
24.08.22	Roche Reports CE Label Expansion Of VENTANA PD-L1 Assay In Non-small Cell Lung Cancer (RTTNews)
24.08.22	Roche's VENTANA PD-L1 (SP263) test gains CE label expansion as a companion diagnostic to identify non-small cell lung cancer patients eligible for Tecentriq (PR Newswire)
23.08.22	Roche Unveils Digital PCR System To Identify Rare And Emerging Disease Mutations (RTTNews)
22.08.22	Roche Develops COVID-19 Test That Detects & Differentiates Omicron Sub-Variant BA.2.75 (RTTNews)
22.08.22	Roche launches COVID-19 test that detects and differentiates the emerging variant of interest BA.2.75 (PR Newswire)
16.08.22	Genentech : FDA Accepts SBLA For Polivy Combination For Aggressive Blood Cancer (RTTNews)
15.08.22	Roche Unveils Elecsys IGRA SARS-CoV-2 Test In Countries That Accept CE Mark (RTTNews)
12.08.22	Roche's Xofluza Wins Expanded FDA Approval To Treat Influenza In Kids Aged Five Years And Older (RTTNews)
11.08.22	Roche Announces FDA Approval Of Label Expansion For VENTANA MMR RxDx Panel (RTTNews)
11.08.22	Roche receives FDA approval for VENTANA MMR RxDx Panel to identify dMMR solid tumour patients and pMMR endometrial cancer patients eligible for KEYTRUDA (PR Newswire)
02.08.22	Genentech's Subcutaneous Formulation Of Tecentriq Shows Positive Results In Phase III Study (RTTNews)
22.07.22	Roche : CHMP Recommends Approval Of Vabysmo For Neovascular AMD And DME (RTTNews)
21.07.22	Roche Names Thomas Schinecker CEO, Severin Schwan Chairman, Effective March, 2023 (RTTNews)
14.07.22	Roche: Longer-term Data With Vabysmo Support Its Continued Use In People With Neovascular AMD (RTTNews)
11.07.22	Roche's Hemlibra Continues To Demonstrate Clinically Meaningful Bleed Control In HAVEN 6 Study (RTTNews)
06.07.22	FDA Grants Priority Review To Genentech's Mosunetuzumab For Refractory Follicular Lymphoma (RTTNews)
29.06.22	Roche Launches BenchMark ULTRA PLUS System For Cancer Diagnostics (RTTNews)
28.06.22	Roche Launches VENTANA DP 600 Slide Scanner For Digital Pathology (RTTNews)
16.06.22	Roche Announces Launch Of Human Papillomavirus Self Sampling Solution - Quick Facts (RTTNews)
16.06.22	Genentech : Alzheimer's Prevention Initiative Study Of Crenezumab Didn't Show Clinical Benefit (RTTNews)
10.06.22	AbbVie : Data Shows Venclyxto/Venclexta Combination Sustained PFS In Chronic Lymphocytic Leukemia (RTTNews)
09.06.22	FDA OKs Foundation Medicine's FoundationOne CDx As Companion Diagnostic For Roche's Rozlytrek (RTTNews)
08.06.22	Roche: EU Approves Lunsumio To Treat Relapsed Or Refractory Follicular Lymphoma (RTTNews)
31.05.22	Genentech: FDA Approves Evrysdi For Babies Under Two Months Of Age With Spinal Muscular Atrophy (RTTNews)
26.05.22	EU Approves Roche's Polivy Combination For Previously Untreated Diffuse Large B-cell Lymphoma (RTTNews)
11.05.22	Genentech : Phase III Study In Non-Small Cell Lung Cancer Fails To Meet Co-primary Endpoint (RTTNews)
29.04.22	Genentech: 3-yr Data Reinforces Efficacy, Safety Of Evrysdi In Infants With Type 1 SMA (RTTNews)
25.04.22	Roche Q1 Group Sales Up 11% At CER (RTTNews)
05.04.22	Roche to showcase the future of diagnostic solutions at EuroMedLab, 10 to 14 April 2022 Munich at ICM International Congress Center (PR Newswire)
04.04.22	Genentech : Ocrevus Data Show Benefit In Disability Progression & Cognitive Decline In SPMS & PPMS (RTTNews)
04.04.22	Genentech's Actemra Intravenous Gets FDA Priority Review To Treat COVID-19 In Hospitalized Adults (RTTNews)
30.03.22	Roche: Phase III SKYSCRAPER-02 Study In ES-SCLC Fails To Meet Co-primary Endpoint (RTTNews)
25.03.22	Roche: CHMP Recommends Approval Of Polivy Combination In Treatment Of Diffuse Large B-cell Lymphoma (RTTNews)
25.03.22	Bristol Myers Squibb, Roche Collaborate To Advance Personalised Healthcare (RTTNews)
25.03.22	Roche announces collaboration with Bristol Myers Squibb to advance personalised healthcare through digital pathology solutions (PR Newswire)
17.03.22	Roche Provides Molecular Testing Solutions To Identify & Differentiate SARS-CoV-2 Omicron Variants (RTTNews)
16.03.22	Roche Announces New Positive Long-term Efficacy And Safety Data For Evrysdi In SMA (RTTNews)
23.02.22	Roche expands the COVID-19 PCR test portfolio to the new cobas 5800 System in countries accepting the CE Mark (PR Newswire)
11.02.22	Genentech : Vabysmo & Susvimo Data Reinforce Potential To Maintain Vision With Fewer Treatments (RTTNews)
03.02.22	Roche FY Profit Down 1% - Quick Facts (RTTNews)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

03.04.25		Roche-Aktie schwächelt: Roche treibt Krebsdiagnostik voran - Forschungsrückschlag mit Ocrevus
05.02.25		Roche punktet bei der FDA: Grünes Licht für Susvimo gegen diabetesbedingte Erblindung - Aktie in Grün
25.06.24		Roche kann EU-Zulassung für Multiple-Sklerose-Mittel an Land ziehen - Aktie sinkt dennoch
10.06.24		Roche-Aktie dennoch tiefer: EU-Kommission lässt Lungenkrebsmedikament Alecensa zu
21.05.24		Roche-Aktie schwächer: Roche-Übernahme von LumiraDx in prüfung - Inavolisib erhält "Breakthrough Therapy"-Status
11.12.23		Roche-Aktie etwas fester: Roche legt Studiendaten zu Kadcyla, Hemlibra, Columvi und Lunsumio vor
02.02.23		Roche-Aktie schwächer: Roche erreicht 2022 Prognose - Umsatz- und Gewinnrückgang im neuen Jahr erwartet
27.12.22		Roche-Aktie leichter: FDA lässt Roches Lymphom-Behandlung Lunsumio zu

03.04.25

Roche-Aktie schwächelt: Roche treibt Krebsdiagnostik voran - Forschungsrückschlag mit Ocrevus

05.02.25

Roche punktet bei der FDA: Grünes Licht für Susvimo gegen diabetesbedingte Erblindung - Aktie in Grün

25.06.24

Roche kann EU-Zulassung für Multiple-Sklerose-Mittel an Land ziehen - Aktie sinkt dennoch

10.06.24

Roche-Aktie dennoch tiefer: EU-Kommission lässt Lungenkrebsmedikament Alecensa zu

21.05.24

Roche-Aktie schwächer: Roche-Übernahme von LumiraDx in prüfung - Inavolisib erhält "Breakthrough Therapy"-Status

11.12.23

Roche-Aktie etwas fester: Roche legt Studiendaten zu Kadcyla, Hemlibra, Columvi und Lunsumio vor

02.02.23

Roche-Aktie schwächer: Roche erreicht 2022 Prognose - Umsatz- und Gewinnrückgang im neuen Jahr erwartet

27.12.22

Roche-Aktie leichter: FDA lässt Roches Lymphom-Behandlung Lunsumio zu

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

Sonova Hldg	262.10	3.39 %	K V
Lonza Grp	584.80	2.38 %	K V
Logitech Intl	66.76	1.71 %	K V
Part Grp Hldg	1’114.00	1.41 %	K V
Swisscom	544.00	0.74 %	K V
ABB	45.07	0.04 %	K V
Novartis	90.91	-0.22 %	K V
Zurich Insur Gr	581.00	-0.34 %	K V
Roche Hldg G	257.60	-0.88 %	K V
Kuehne+Nagel Int	177.85	-3.24 %	K V

Roche Aktie VALOR 224184 / ISIN US7711951043

Nachrichten zu Roche Holding AG Sponsored American Deposit Receipt Repr 1/2 NVTGSh

Aktien Top/Flop

Roche Peer Group Nachrichten

Meistgelesene Nachrichten